Aegerion Pharmaceuticals has reported the positive results from the Phase III clinical trial of lomitapide when used as a treatment for homozygous familial hypercholesterolemia.
The Phase III trial included 29 patients and showed that the drug reduced low-density lipoprotein cholesterol and triglyceride levels in patients with homozygous familial hypercholesterolemia and familial chylomicronemia.
The study also demonstrated the efficacy and long-term safety of the drug when used to treat homozygous familial hypercholesterolemia.
The adverse affects seen with the drug candidate include mild-to-moderate gastrointestinal problems.
Homozygous familial hypercholesterolemia is characterised by elevated levels of low-density lipoprotein cholesterol, which can lead to life-threatening cardiovascular events.
